Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Halozyme Therapeutics (HALO) Posts Q4 EPS of $0.50
February 23, 2021 4:20 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.50, which may not compare to the analyst estimate of $0.53. Revenue for the quarter came in at $121.7 million versus the consensus estimate of $120.16 million.
GUIDANCE:
Halozyme Therapeutics sees FY2021 EPS of $1.40-$1.55,... More
